dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Signs and Symptoms

Definition

  • Refers to pain or discomfort centered in the upper abdomen
    • Discomfort refers to a subjective sensation that the patient does not interpret as pain which may be characterized by or associated with upper abdominal fullness, early satiety, bloating, belching, nausea and vomiting (N/V)
    • Centered refers to pain or discomfort in or around the midline
  • Dyspepsia is considered a symptom complex rather than a specific diagnosis

Signs and Symptoms

  • Ulcer-like
    • Chronic or recurrent epigastric pain or discomfort for at least 2-4 weeks
  • Reflux-like
    • Acid regurgitation
    • Heartburn
  • Dysmotility-like
    • Bloating in upper abdomen not accompanied by visible distension
    • Early satiety
    • N/V
    • Postprandial fullness
    • Upper abdominal discomfort often aggravated by food
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 3 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

6 days ago
Treatment with tradipitant in patients with idiopathic or diabetic gastroparesis produces meaningful improvements in nausea and vomiting, according to the results of a phase II trial.